{"id":"group-3-liposomal-amphotericin-b","safety":{"commonSideEffects":[{"rate":null,"effect":"Nephrotoxicity"},{"rate":null,"effect":"Infusion-related reactions (fever, chills, rigors)"},{"rate":null,"effect":"Hypokalemia"},{"rate":null,"effect":"Anemia"},{"rate":null,"effect":"Hypomagnesemia"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Amphotericin B is a polyene antifungal that inserts into the fungal cell membrane and forms pores, leading to leakage of cellular contents and fungal cell lysis. The liposomal formulation reduces toxicity to human cells by preferentially delivering the drug to fungal cells and infected tissues while minimizing exposure to healthy host cells.","oneSentence":"Liposomal amphotericin B binds to ergosterol in fungal cell membranes, disrupting membrane integrity and causing cell death.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:14:23.141Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Invasive fungal infections (e.g., candidiasis, aspergillosis, cryptococcosis)"},{"name":"Amphotericin B-resistant fungal infections"}]},"trialDetails":[{"nctId":"NCT07337720","phase":"NA","title":"Liposomal Amphotericin B in Invasive Aspergillosis With Hepatic Dysfunction","status":"NOT_YET_RECRUITING","sponsor":"Southeast University, China","startDate":"2025-12-20","conditions":"Aspergillosis Invasive","enrollment":40},{"nctId":"NCT06666322","phase":"PHASE2, PHASE3","title":"Platform Trial For Cryptococcal Meningitis","status":"RECRUITING","sponsor":"University of Minnesota","startDate":"2025-05-28","conditions":"Hiv, Cryptococcal Meningitis","enrollment":2000},{"nctId":"NCT07185503","phase":"","title":"Liposomal Amphotericin B Plus Posaconazole/Isavuconazole for Mucormycosis in Hematologic Malignancies: Efficacy and Safety","status":"RECRUITING","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2025-03-25","conditions":"Mucormycosis in Hematologic Malignancies","enrollment":60},{"nctId":"NCT06414512","phase":"PHASE2","title":"Optimizing the Dose of Flucytosine for the Treatment of Cryptococcal Meningitis","status":"COMPLETED","sponsor":"University of Minnesota","startDate":"2024-04-09","conditions":"Cryptococcal Meningitis","enrollment":48},{"nctId":"NCT07135778","phase":"","title":"Liposomal Amphotericin B and Isavuconazole/Posaconazole in Br-IFD（ Breakthrough Invasive Fungal Disease） in Patients With Malignant Hematological Diseases","status":"RECRUITING","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2025-05-19","conditions":"Invasive Fungal Disease","enrollment":36},{"nctId":"NCT04157465","phase":"NA","title":"Anti-fungal Strategies in Acute-on-Chronic Liver Failure Patients","status":"COMPLETED","sponsor":"Post Graduate Institute of Medical Education and Research, Chandigarh","startDate":"2019-11-07","conditions":"Antifungal Agents, Invasive Fungal Infections, Mycoses","enrollment":216},{"nctId":"NCT05814432","phase":"PHASE3","title":"Efficacy and Safety of High-dose Liposomal Amphotericin B for Disseminated Histoplasmosis in AIDS","status":"RECRUITING","sponsor":"Federal University of Health Science of Porto Alegre","startDate":"2025-01-16","conditions":"Disseminated Histoplasma Capsulatum Infection, AIDS and Infections, Immunosuppression","enrollment":279},{"nctId":"NCT04799236","phase":"PHASE3","title":"Treatment of Mucosal Bolivian Leishmaniasis","status":"RECRUITING","sponsor":"Fundacion Nacional de Dermatologia","startDate":"2021-04-01","conditions":"Mucosal Leishmaniasis","enrollment":120},{"nctId":"NCT00696969","phase":"PHASE3","title":"Safety and Efficacy Study to Evaluate Different Combination Treatment Regimens for Visceral Leishmaniasis","status":"COMPLETED","sponsor":"Drugs for Neglected Diseases","startDate":"2008-06","conditions":"Visceral Leishmaniasis","enrollment":634}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":243,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Group 3: Liposomal amphotericin B","genericName":"Group 3: Liposomal amphotericin B","companyName":"Fundacion Nacional de Dermatologia","companyId":"fundacion-nacional-de-dermatologia","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Liposomal amphotericin B binds to ergosterol in fungal cell membranes, disrupting membrane integrity and causing cell death. Used for Invasive fungal infections (e.g., candidiasis, aspergillosis, cryptococcosis), Amphotericin B-resistant fungal infections.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}